Previous close | 219.21 |
Open | 219.51 |
Bid | 0.00 x 800 |
Ask | 0.00 x 900 |
Day's range | 217.05 - 219.85 |
52-week range | 156.72 - 231.86 |
Volume | |
Avg. volume | 1,236,248 |
Market cap | 62.375B |
Beta (5Y monthly) | 1.10 |
PE ratio (TTM) | 45.45 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.28 (1.04%) |
Ex-dividend date | 18 Mar 2024 |
1y target est | N/A |
Masimo's (MASI) R&D activities raise optimism about the stock.
CVRx's (CVRX) announcement of the availability of additional data supporting the long-term benefits of Barostim is likely to lead to improved patient care.
Outset Medical's (OM) latest agreement is likely to provide patients and caregivers access to innovative home dialysis with the Tablo Hemodialysis System.